4.7 Article

ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures

期刊

CLINICAL MICROBIOLOGY AND INFECTION
卷 18, 期 -, 页码 9-18

出版社

ELSEVIER SCI LTD
DOI: 10.1111/1469-0691.12038

关键词

Biomarkers; Candida; diagnosis; guideline; noncultural

资金

  1. Astellas Pharma
  2. bioMerieux
  3. Gilead Sciences
  4. Merck Sharp and Dohme
  5. Pfizer
  6. Schering-Plough
  7. Soria Melguizo SA
  8. Ferrer International
  9. European Union
  10. ALBAN program
  11. Spanish Agency for International Cooperation
  12. Spanish Ministry of Culture and Education
  13. Spanish Health Research Fund
  14. Instituto de Salud Carlos III
  15. Ramon Areces Foundation
  16. Mutua Madrilena Foundation
  17. Astellas
  18. Cephalon
  19. Merck
  20. Merck Sharp
  21. Dohme
  22. MSD
  23. Baxter
  24. Dohme-Chibret AG
  25. Roche Diagnostic
  26. German Federal Ministry of Research and Education (BMBF) [01KN1106]
  27. Gilead
  28. Sharp Dohme
  29. Schering
  30. National Institute of Health Research (NIHR)
  31. Medical Research Council
  32. National Institute for the Replacement, Refinement and Reduction, of Animals in Research
  33. Bio-Merieux
  34. Astra Zeneca
  35. Novartis
  36. GSK
  37. Enzon
  38. Schering Merck
  39. Wyeth
  40. Aventis
  41. Abbott
  42. BMS
  43. MSD (Schering-Plough)
  44. National Institute for Health Research [CS/08/08/10] Funding Source: researchfish

向作者/读者索取更多资源

Clin Microbiol Infect 2012; 18 (Suppl. 7): 918 Abstract As the mortality associated with invasive Candida infections remains high, it is important to make optimal use of available diagnostic tools to initiate antifungal therapy as early as possible and to select the most appropriate antifungal drug. A panel of experts of the European Fungal Infection Study Group (EFISG) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) undertook a data review and compiled guidelines for the clinical utility and accuracy of different diagnostic tests and procedures for detection of Candida infections. Recommendations about the microbiological investigation and detection of candidaemia, invasive candidiasis, chronic disseminated candidiasis, and oropharyngeal, oesophageal, and vaginal candidiasis were included. In addition, remarks about antifungal susceptibility testing and therapeutic drug monitoring were made.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据